---
layout: default
title: Cytarabine
description: "Cytarabine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 9 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 53
evidence_level: L5
indication_count: 9
---

# Cytarabine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>9</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Cytarabine è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Cytarabine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Cytarabine (Ara-C) æ˜¯æ²»ç™‚æ€¥æ€§ç™½è¡€ç—…çš„æ ¸å¿ƒåŒ–ç™‚è—¥ç‰©ï¼ŒTxGNN é æ¸¬å…¶å°å°ç´°èƒè‚ºç™ŒåŠåŸç™¼æ€§è‚ºæ·‹å·´ç˜¤æœ‰ç™‚æ•ˆï¼Œé€™äº›é æ¸¬æœ‰æ­·å²è‡¨åºŠç ”ç©¶æ”¯æŒï¼Œä½†ç™‚æ•ˆæœ‰é™ä¸”éç¾ä»£æ¨™æº–æ²»ç™‚ã€‚
</p>


---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Cytarabine (é˜¿ç³–èƒè‹·, Ara-C) |
| DrugBank ID | DB00987 |
| å°ç£å•†å“å | è¤‡æ–¹è£½åŠ‘ä¸­çš„æˆåˆ†ï¼Œå¦‚ Midostaurin ä½µç”¨æ–¹æ¡ˆ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | æ€¥æ€§éª¨é«“æ€§ç™½è¡€ç—… (AML)ã€æ…¢æ€§æ·‹å·´çƒæ€§ç™½è¡€ç—… (CLL)ã€èˆ‡å…¶ä»–è—¥ç‰©ä½µç”¨ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | small cell lung carcinomaã€primary pulmonary lymphomaã€well-differentiated fetal adenocarcinoma of the lungã€pulmonary blastomaã€myeloid leukemiaã€upper aerodigestive tract neoplasmã€ganglioneuroblastoma (disease)ã€vertebral anomalies and variable endocrine and T-cell dysfunctionã€è…¹è†œå¾Œè…«ç˜¤ |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.998 (small cell lung carcinoma) |
| è­‰æ“šç­‰ç´š | L3 (æ­·å²è‡¨åºŠç ”ç©¶ï¼Œéç¾ä»£æ¨™æº–) |

---

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

Cytarabine çš„æŠ—è…«ç˜¤æ©Ÿè½‰æ”¯æŒå…¶å°å¤šç¨®æƒ¡æ€§è…«ç˜¤çš„æ½›åœ¨æ´»æ€§ï¼š

1. **æ ¸è‹·é¡ä¼¼ç‰©**ï¼šCytarabine æ˜¯èƒå˜§å•¶æ ¸è‹·çš„é¡ä¼¼ç‰©ï¼Œå¹²æ“¾ DNA åˆæˆ
2. **S æœŸç‰¹ç•°æ€§**ï¼šä¸»è¦ä½œç”¨æ–¼ DNA åˆæˆæœŸï¼Œå°å¿«é€Ÿåˆ†è£‚çš„è…«ç˜¤ç´°èƒæœ‰é¸æ“‡æ€§
3. **å»£è­œæ´»æ€§**ï¼šæ­·å²ä¸Šæ›¾ç”¨æ–¼å¤šç¨®æƒ¡æ€§è…«ç˜¤çš„æ¢ç´¢æ€§æ²»ç™‚

### é æ¸¬é©æ‡‰ç—‡åˆ†æ

| é æ¸¬é©æ‡‰ç—‡ | æ©Ÿè½‰åˆç†æ€§ | æ­·å²ç ”ç©¶ |
|------------|------------|----------|
| å°ç´°èƒè‚ºç™Œ | é«˜ - SCLC åˆ†è£‚é€Ÿåº¦å¿« | 1970-1990 å¹´ä»£æœ‰å¤šé …ç ”ç©¶ |
| åŸç™¼æ€§è‚ºæ·‹å·´ç˜¤ | é«˜ - æ·‹å·´ç˜¤å° Ara-C æ•æ„Ÿ | ç”¨æ–¼ CNS æ·‹å·´ç˜¤åŠå¾©ç™¼æ€§æ·‹å·´ç˜¤ |

---

## è‡¨åºŠè©¦é©—è­‰æ“š

### å°ç´°èƒè‚ºç™Œç›¸é—œè©¦é©—

| è©¦é©—ç·¨è™Ÿ | æ¨™é¡Œ | éšæ®µ | ç‹€æ…‹ | ç›¸é—œæ€§ |
|----------|------|------|------|--------|
| NCT03507244 | é˜å…§ Pemetrexed æ²»ç™‚è…¦è†œè½‰ç§» | Phase 1/2 | å·²å®Œæˆ | æåŠ cytarabine ä½œç‚ºå°ç…§ |
| NCT03101579 | é˜å…§ Pemetrexed æ²»ç™‚ NSCLC è…¦è†œè½‰ç§» | Phase 1 | å·²å®Œæˆ | Cytarabine ä½œç‚ºå‚³çµ±é˜å…§æ²»ç™‚æ¯”è¼ƒ |

### æ·‹å·´ç˜¤ç›¸é—œè©¦é©—

| è©¦é©—ç·¨è™Ÿ | æ¨™é¡Œ | éšæ®µ | ç‹€æ…‹ | ç™¼ç¾ |
|----------|------|------|------|------|
| NCT00345865 | æ·‹å·´ç˜¤è‡ªé«”ç§»æ¤ | Phase 2 | å·²å®Œæˆ | Cytarabine ç‚ºæ¢ä»¶ç™‚æ³•ä¸€éƒ¨åˆ† |
| NCT00452374 | Oxaliplatin + Fludarabine + Ara-C + Rituximab | Phase 1/2 | å·²å®Œæˆ | ç”¨æ–¼ Richter è½‰åŒ–åŠ CLL |

---

## æ–‡ç»è­‰æ“š

### å°ç´°èƒè‚ºç™Œ

| PMID | æ¨™é¡Œ | å¹´ä»½ | ä¸»è¦ç™¼ç¾ |
|------|------|------|----------|
| 232239 | Combination radiotherapy and chemotherapy for SCLC | 1979 | Ara-C ä½µç”¨æ–¹æ¡ˆæœ‰æ•ˆä½†ç„¡å„ªå‹¢ |
| 3030547 | High-dose cytarabine in SCLC | 1987 | é«˜åŠ‘é‡ Ara-C å–®ç¨ä½¿ç”¨åæ‡‰æœ‰é™ |
| 6095640 | Intensive cytosine arabinoside therapy in SCLC | 1984 | Ara-C åŠ å…¥ CAV æ–¹æ¡ˆç„¡é¡å¤–ç›Šè™• |
| 2841844 | VP-16 and Ara-C for relapsed SCLC | 1988 | å¾©ç™¼ SCLC æ²»ç™‚ï¼Œæ¯’æ€§é«˜ä½†æ´»æ€§æœ‰é™ |

**æ–‡ç»çµè«–**ï¼š1980 å¹´ä»£çš„ç ”ç©¶é¡¯ç¤º cytarabine å° SCLC æœ‰ä¸€å®šæ´»æ€§ï¼Œä½†ä¸¦æœªå„ªæ–¼ç•¶æ™‚çš„æ¨™æº–æ–¹æ¡ˆï¼Œä¸”æ¯’æ€§é¡¯è‘—ã€‚

### åŸç™¼æ€§ CNS æ·‹å·´ç˜¤

| PMID | æ¨™é¡Œ | å¹´ä»½ | ä¸»è¦ç™¼ç¾ |
|------|------|------|----------|
| 12860951 | Chemotherapy for primary CNS lymphoma in elderly | 2003 | MTX + Ara-C å°è€å¹´æ‚£è€…æœ‰æ•ˆ |
| 12241119 | HD-MTX and Ara-C for primary CNS lymphoma | 2002 | 100% åæ‡‰ç‡ï¼Œ86% CR |
| 15957966 | Management of leptomeningeal malignancy | 2005 | Ara-C ç‚ºè…¦è†œç™Œç—‡çš„æ¨™æº–é˜å…§æ²»ç™‚ |

**æ–‡ç»çµè«–**ï¼šCytarabineï¼ˆç‰¹åˆ¥æ˜¯é«˜åŠ‘é‡æˆ–é˜å…§çµ¦è—¥ï¼‰æ˜¯ CNS æ·‹å·´ç˜¤æ²»ç™‚çš„é‡è¦æˆåˆ†ã€‚

---

## å°ç£ä¸Šå¸‚è³‡è¨Š

Cytarabine åœ¨å°ç£ä¸»è¦ä»¥ä¸‹åˆ—å½¢å¼ä½¿ç”¨ï¼š

| ç”¨é€” | è—¥å“ | èªªæ˜ |
|------|------|------|
| AML å‰å°æ²»ç™‚ | Midostaurin (å½Œå¤šå¦¥) ä½µç”¨ | FLT3 çªè®Šé™½æ€§ AML |
| AML éå›ºæ²»ç™‚ | é«˜åŠ‘é‡ Ara-C | æ¨™æº–æ–¹æ¡ˆ |
| CLL æ²»ç™‚ | Venetoclax ä½µç”¨ä½åŠ‘é‡ Ara-C | ä¸é©åˆå¼·åŒ–åŒ–ç™‚çš„æ‚£è€… |

---

## å®‰å…¨æ€§è€ƒé‡

### ä¸»è¦æ¯’æ€§

| æ¯’æ€§é¡å‹ | è¡¨ç¾ | ç®¡ç† |
|----------|------|------|
| éª¨é«“æŠ‘åˆ¶ | åš´é‡å—œä¸­æ€§çƒä½ä¸‹ã€è¡€å°æ¿ä½ä¸‹ | ç›£æ¸¬ CBCï¼Œé é˜²æ€§ä½¿ç”¨ G-CSF |
| æ„ŸæŸ“ | æ©Ÿæœƒæ€§æ„ŸæŸ“é¢¨éšªé«˜ | é é˜²æ€§æŠ—ç”Ÿç´ ã€æŠ—é»´èŒè—¥ |
| ç¥ç¶“æ¯’æ€§ | é«˜åŠ‘é‡æ™‚å¯èƒ½å‡ºç¾å°è…¦ç—‡ç‹€ | ç›£æ¸¬ç¥ç¶“åŠŸèƒ½ï¼Œèª¿æ•´åŠ‘é‡ |
| æ¶ˆåŒ–é“ | é»è†œç‚ã€å™å¿ƒå˜”å | æ­¢åè—¥ã€å£è…”è­·ç† |
| Ara-C ç—‡å€™ç¾¤ | ç™¼ç‡’ã€è‚Œç—›ã€éª¨ç—›ã€çš®ç–¹ | é¡å›ºé†‡é é˜² |

### è—¥ç‰©äº¤äº’ä½œç”¨æ³¨æ„

- **å…¶ä»–éª¨é«“æŠ‘åˆ¶è—¥ç‰©**ï¼šæ¯’æ€§ç–ŠåŠ 
- **Digoxin**ï¼šå¯èƒ½é™ä½ digoxin å¸æ”¶
- **Flucytosine**ï¼šç«¶çˆ­æ€§æ‹®æŠ—

---


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages mod...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modifie...

**Infections** ğŸŸ¢ Minor
- Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All pat...

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cyto...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬è©•ä¼°

| è©•ä¼°é …ç›® | å°ç´°èƒè‚ºç™Œ | åŸç™¼æ€§è‚ºæ·‹å·´ç˜¤ |
|----------|------------|----------------|
| æ©Ÿè½‰åˆç†æ€§ | é«˜ | é«˜ |
| è‡¨åºŠè­‰æ“š | L3 (æ­·å²ç ”ç©¶) | L2 (CNS æ·‹å·´ç˜¤æœ‰ RCT) |
| æ–‡ç»æ”¯æŒ | ä¸­ç­‰ä½†éæ™‚ | è¼ƒå¼·ï¼ˆç”¨æ–¼ CNS æ·‹å·´ç˜¤ï¼‰ |

### è‡¨åºŠæ„ç¾©è©•ä¼°

#### å°ç´°èƒè‚ºç™Œ

- **ä¸å»ºè­°è‡¨åºŠä½¿ç”¨**ï¼šç¾ä»£ SCLC æ²»ç™‚å·²ä¸åŒ…å« cytarabine
- **ç¾ä»£æ¨™æº–**ï¼šCisplatin/Carboplatin + Etoposideï¼Œå…ç–«æ²»ç™‚ (å¦‚ atezolizumab)
- **æ­·å²åƒ¹å€¼**ï¼šåæ˜ äº†çŸ¥è­˜åœ–è­œèƒ½æ•æ‰æ­·å²ç”¨è—¥é—œè¯

#### åŸç™¼æ€§è‚ºæ·‹å·´ç˜¤/CNS æ·‹å·´ç˜¤

- **æœ‰è‡¨åºŠåƒ¹å€¼**ï¼šé«˜åŠ‘é‡ Ara-C æ˜¯ CNS æ·‹å·´ç˜¤æ²»ç™‚çš„é‡è¦æˆåˆ†
- **ç¾ä»£æ–¹æ¡ˆ**ï¼šé€šå¸¸èˆ‡ MTXã€rituximab ä½µç”¨
- **æ³¨æ„äº‹é …**ï¼šã€ŒåŸç™¼æ€§è‚ºæ·‹å·´ç˜¤ã€è¼ƒç½•è¦‹ï¼Œæ²»ç™‚é€šå¸¸åƒè€ƒå…¨èº«æ€§æ·‹å·´ç˜¤æ–¹æ¡ˆ

### å»ºè­°

1. **SCLC**ï¼šä¸å»ºè­°ä½¿ç”¨ cytarabineï¼Œæ‡‰ä¾å¾ªç¾ä»£æ²»ç™‚æŒ‡å¼•
2. **CNS æ·‹å·´ç˜¤**ï¼šé«˜åŠ‘é‡ cytarabine ä»æœ‰å…¶è§’è‰²ï¼Œéœ€ç”±è¡€æ¶²è…«ç˜¤å°ˆç§‘è©•ä¼°
3. **è…¦è†œè½‰ç§»**ï¼šé˜å…§ cytarabine æˆ– liposomal cytarabine ç‚ºå¯é¸æ–¹æ¡ˆ

### æ•´é«”è­‰æ“šç­‰ç´š

**L3 (è§€å¯Ÿæ€§ç ”ç©¶/æ­·å²è‡¨åºŠç¶“é©—)** - æœ‰æ–‡ç»æ”¯æŒä½†éç¾ä»£æ¨™æº–æ²»ç™‚

---

*æœ¬ç­†è¨˜åƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚ä»»ä½•ç”¨è—¥æ±ºç­–æ‡‰è«®è©¢å°ˆæ¥­é†«ç™‚äººå“¡ã€‚*

*æœ€å¾Œæ›´æ–°ï¼š2026-02-11*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Raloxifene]({{ "/drugs/raloxifene/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Brivaracetam]({{ "/drugs/brivaracetam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Flunitrazepam]({{ "/drugs/flunitrazepam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Clomipramine]({{ "/drugs/clomipramine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tenofovir Alafenamide]({{ "/drugs/tenofovir_alafenamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Cytarabineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/cytarabine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_cytarabine,
  title = {Cytarabineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/cytarabine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
